相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Sunitinib in Metastatic Renal Cell Carcinoma Patients With Brain Metastases
Martin E. Gore et al.
CANCER (2011)
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
B. Neyns et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Jean-Pascal H. Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas
O. Martinho et al.
BRITISH JOURNAL OF CANCER (2009)
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre et al.
LANCET ONCOLOGY (2009)
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide
Qingyu Zhou et al.
CLINICAL CANCER RESEARCH (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy
Frederic Thibault et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas
Marjut Puputti et al.
MOLECULAR CANCER RESEARCH (2006)
Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme
H Joensuu et al.
JOURNAL OF PATHOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate
M Furuhashi et al.
CANCER RESEARCH (2004)
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors
A Abramsson et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft
DF Stefanik et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo
C Dai et al.
GENES & DEVELOPMENT (2001)